Skip to content

The Effect Of Venous Magnesium Sulfate On Pain Relief In Patients With Acute Renal Colic

Evaluation Of The Effect Of Intravenous Magnesium Sulfate On Pain Relief In Patients With Acute Renal Colic- A Randomized Double Blind Clinical Trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20171206037774N1
Enrollment
90
Registered
2018-02-04
Start date
2018-01-21
Completion date
Unknown
Last updated
2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Renal Colic. Renal Colic

Interventions

Intervention 1: Intervention Group: Patients With Acute Renal Colic In This Group Received Magnesium Sulfate At A Dose Of 2 G Of 50% Solution At 100 Cc At 15 Minutesmagnesium sulfate at a dose of 2 g

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: The Adult Patients With Acute Renal Colic Are Between The Ages Of 18-60 And The Severity Of Pain Between 6 To 10 Based On The VAS Criteria And GCS= 15.

Exclusion criteria

Exclusion criteria: Pregnancy Or Suspicion Of Pregnancy, History Of Alcohol Addiction Sensitization To Morphine Or Pain Medication, History Of Mental Illness And Depression And Recent Sedation Or Antipsychotics And Calcium Intake Of Blocker Channel, History Of Drug Dependence, Receiving Analgesic In 6 Recent Illness, Neuromascular Disease And Underlying Bradycardia (Heart Rate Less Than 60), Long Qrs Interval, History Of Heart And Kidney Disease, Liver And Liver Disease, Seizure And History Of Drop In Pressure, Abdominal Pain And Probability Of Peritonitis, Lack Of Consent Of The Patient From Continuing The Study, Unstable Patient With Clinical Condition And Pressure Drop (Systolic Pressure Less Than 90 Or Pressure Foot 20% Of The Base) And A Drop In Heart Rate To Less Than 8, And A Drop In Respiratory Rate To Less Than 60 During The Study.

Design outcomes

Primary

MeasureTime frame
Reducing Pain. Timepoint: 20, 30, 60, 120, 180 min. Method of measurement: VAS.

Secondary

MeasureTime frame
Side Effect. Timepoint: 180 min. Method of measurement: Observation.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Arehemi Dolatabadi

Shahid Beheshti University of Medical Sciences

dr.fatemeh.derakhshani62@gmail.com+98 21 25719

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026